GlassScriptPhysician profile
Demaceo Howard
NPI 1225006752
$39,185.47
in general payments reported to CMS, 2019-2025
26 companies · $840 in 2025
The $840 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $1,179 · 2021: $1,907 · 2022: $1,013 · 2023: $934 · 2024: $1,640 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,363 · Education: $50.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,362.67 |
| Education | $50.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $30,081.00 | 2019 | |
| Abbott Laboratories | $3,510.31 | 2019-2024 | Proclaim, Octrode, Eterna |
| Medtronic, INC. | $2,174.45 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Medtronic USA, INC. | $889.42 | 2019-2020 | |
| Nevro Corp. | $753.53 | 2019-2023 | Senza |
| Boston Scientific Corporation | $498.25 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Spectra Wavewriter |
| Pfizer INC. | $195.48 | 2023-2024 | |
| Collegium Pharmaceutical, INC. | $162.08 | 2019-2021 | |
| Curonix LLC | $148.81 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Mml US, INC. | $130.25 | 2024 | Reactiv8 |
| Scilex Pharmaceuticals INC. | $111.74 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $94.14 | 2019 | |
| Biodelivery Sciences International, INC. | $91.26 | 2019-2021 | |
| Painteq LLC | $45.33 | 2024 | Painteq |
| Spinal Simplicity, LLC | $40.98 | 2024 | Ha Minuteman G3-R |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $36.15 | 2022-2024 | Kloxxado |
| Virtus Pharmaceuticals LLC | $33.57 | 2021 | |
| Spr Therapeutics, INC | $32.16 | 2023-2025 | Sprint Pns System |
| Si-Bone, INC. | $28.61 | 2023 | |
| Grt US Holding, INC. | $25.55 | 2021 | |
| Assertio Therapeutics, INC. | $21.45 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $18.64 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $17.38 | 2024 | Kristalose |
| Saluda Medical Americas, INC. | $16.71 | 2025 | Evoke |
| Avanos Medical | $16.02 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Demaceo Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.